FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910644531> ?p ?o ?g. }

• W2910644531 endingPage "77" @default.
• W2910644531 startingPage "69" @default.
• W2910644531 abstract "BackgroundSunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.Materials and methodsIn a phase 2 trial, 117 patients with metastatic clear cell renal cell cancer were started on sunitinib 50 mg/day with the aim to treat for 28 days. Treatment breaks were reduced to 7 days. Sunitinib dose and the number of days on therapy were individualised based on toxicity aiming for ≤ grade II toxicity with dose escalation in patients with minimal toxicity. The null hypothesis for the primary end-point was a progression-free survival (PFS) of 8.5 months based on a study with similar eligibility criteria.ResultsThe null hypothesis was rejected (p < 0.001) with a median PFS of 12.5 months (95% confidence interval [CI]: 9.6–16.5). The median overall survival was 38.5 months (95% CI: 28.3-not reached). The objective response rate (46.1%) and stable disease rate (38.5%) translated into a clinical benefit for 84.6% of patients with no decline in quality of life scores during therapy. Fewer patients were dose reduced (26.5% vs. 50%) or discontinued due to toxicity (7.7 vs. 18–20%) compared to standard sunitinib dosing, and 20 (18.4%) patients were dose escalated to 62.5 mg (12) and 75 mg (8) with a wide individual variation in the optimal dose and treatment duration.Conclusions: Individualised sunitinib therapy is feasible, safe and an effective method to manage toxicity with one of the best efficacy seen for oral vascular endothelial growth factor inhibitors in metastatic renal cell carcinoma.Clinicaltrials.gov identifierNCT01499121." @default.
• W2910644531 created "2019-01-25" @default.
• W2910644531 creator A5007564512 @default.
• W2910644531 creator A5013185325 @default.
• W2910644531 creator A5028194267 @default.
• W2910644531 creator A5028677586 @default.
• W2910644531 creator A5037646183 @default.
• W2910644531 creator A5042123586 @default.
• W2910644531 creator A5057439948 @default.
• W2910644531 creator A5058331275 @default.
• W2910644531 creator A5058744796 @default.
• W2910644531 creator A5060092380 @default.
• W2910644531 creator A5061327271 @default.
• W2910644531 creator A5061626918 @default.
• W2910644531 creator A5064078958 @default.
• W2910644531 creator A5068644454 @default.
• W2910644531 creator A5070791578 @default.
• W2910644531 creator A5075361066 @default.
• W2910644531 creator A5076375756 @default.
• W2910644531 creator A5082371740 @default.
• W2910644531 creator A5087150696 @default.
• W2910644531 creator A5089306688 @default.
• W2910644531 date "2019-02-01" @default.
• W2910644531 modified "2023-10-17" @default.
• W2910644531 title "The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial" @default.
• W2910644531 cites W1983294325 @default.
• W2910644531 cites W1994295819 @default.
• W2910644531 cites W2052683946 @default.
• W2910644531 cites W2096523159 @default.
• W2910644531 cites W2099088585 @default.
• W2910644531 cites W2103689170 @default.
• W2910644531 cites W2105258029 @default.
• W2910644531 cites W2112075556 @default.
• W2910644531 cites W2114991862 @default.
• W2910644531 cites W2116949558 @default.
• W2910644531 cites W2117125017 @default.
• W2910644531 cites W2155319477 @default.
• W2910644531 cites W2162352067 @default.
• W2910644531 cites W2520608163 @default.
• W2910644531 cites W2566554957 @default.
• W2910644531 cites W2567139842 @default.
• W2910644531 cites W2582243751 @default.
• W2910644531 cites W2783439892 @default.
• W2910644531 cites W2785838318 @default.
• W2910644531 cites W2790729376 @default.
• W2910644531 cites W2792937256 @default.
• W2910644531 cites W2797198618 @default.
• W2910644531 cites W4229769653 @default.
• W2910644531 cites W4244491773 @default.
• W2910644531 doi "https://doi.org/10.1016/j.ejca.2018.12.006" @default.
• W2910644531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30648632" @default.
• W2910644531 hasPublicationYear "2019" @default.
• W2910644531 type Work @default.
• W2910644531 sameAs 2910644531 @default.
• W2910644531 citedByCount "24" @default.
• W2910644531 countsByYear W29106445312019 @default.
• W2910644531 countsByYear W29106445312020 @default.
• W2910644531 countsByYear W29106445312021 @default.
• W2910644531 countsByYear W29106445312022 @default.
• W2910644531 countsByYear W29106445312023 @default.
• W2910644531 crossrefType "journal-article" @default.
• W2910644531 hasAuthorship W2910644531A5007564512 @default.
• W2910644531 hasAuthorship W2910644531A5013185325 @default.
• W2910644531 hasAuthorship W2910644531A5028194267 @default.
• W2910644531 hasAuthorship W2910644531A5028677586 @default.
• W2910644531 hasAuthorship W2910644531A5037646183 @default.
• W2910644531 hasAuthorship W2910644531A5042123586 @default.
• W2910644531 hasAuthorship W2910644531A5057439948 @default.
• W2910644531 hasAuthorship W2910644531A5058331275 @default.
• W2910644531 hasAuthorship W2910644531A5058744796 @default.
• W2910644531 hasAuthorship W2910644531A5060092380 @default.
• W2910644531 hasAuthorship W2910644531A5061327271 @default.
• W2910644531 hasAuthorship W2910644531A5061626918 @default.
• W2910644531 hasAuthorship W2910644531A5064078958 @default.
• W2910644531 hasAuthorship W2910644531A5068644454 @default.
• W2910644531 hasAuthorship W2910644531A5070791578 @default.
• W2910644531 hasAuthorship W2910644531A5075361066 @default.
• W2910644531 hasAuthorship W2910644531A5076375756 @default.
• W2910644531 hasAuthorship W2910644531A5082371740 @default.
• W2910644531 hasAuthorship W2910644531A5087150696 @default.
• W2910644531 hasAuthorship W2910644531A5089306688 @default.
• W2910644531 hasBestOaLocation W29106445311 @default.
• W2910644531 hasConcept C126322002 @default.
• W2910644531 hasConcept C126894567 @default.
• W2910644531 hasConcept C141071460 @default.
• W2910644531 hasConcept C143998085 @default.
• W2910644531 hasConcept C197934379 @default.
• W2910644531 hasConcept C203092338 @default.
• W2910644531 hasConcept C2777288759 @default.
• W2910644531 hasConcept C2777472916 @default.
• W2910644531 hasConcept C2779490328 @default.
• W2910644531 hasConcept C29730261 @default.
• W2910644531 hasConcept C31760486 @default.
• W2910644531 hasConcept C44249647 @default.
• W2910644531 hasConcept C535046627 @default.
• W2910644531 hasConcept C71924100 @default.
• W2910644531 hasConceptScore W2910644531C126322002 @default.
• W2910644531 hasConceptScore W2910644531C126894567 @default.

• next